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Results: Four children, female, ages 3.7, 5.2, 5.4 and 12 
years (patients 1 to 4), were diagnosed between February 
and July 2013 with DIPG. They were treated initially with 
radiochemotherapy. Patients 1, 2 and 4 have received 54 Gy 
of conformal RT including the primary tumor with margins. 
The third patient initiated RT as scheduled but had to 
interrupt it after the administration of 14.4 Gy due to a 
severe CNS infection (ventriculitis). RT was withheld until the 
event of clinical progression. Patients 2 and 4 received 
weekly carboplatin and vincristine as first line treatment. 
Patient 1 received temozolomide during and after RT. Patient 
3 was scheduled to receive high dose chemotherapy 
(cisplatin, vincristine and etoposide) during RT, but only 
completed the first cycle of the planned treatment. The 
progression-free survival after first line treatment was 10.3, 
6.7, 10.4 and 15.1 months. The doses of the re-irradiation 
were 45, 27, 45 and 18 Gy. Second-line chemotherapy was 
temozolomide for patients 1 and 4. Overall survival after re-
irradiation was 4.9, 4.2, 9.9 and 4.4 months. All patients had 
some degree of clinical benefit with re-irradiation, ranging 
from stopping steroids to minor symptom amelioration. 
Patients 2 and 4 had stable disease in image evaluation (MRI) 
after re-irradiation. The other patients were not evaluated 
with imaging. No patient had side effects related to re-
irradiation therapy. 
Conclusions: In this small case series report, re-irradiation 
for pediatric patients with progressive DIPG was feasible, 
safe, and associated with clinically meaningful results. As no 
other treatment modality can offer any possibility of 
response in this subset of patients, re-irradiation is a good 
candidate to be rapidly incorporated into routine clinical 
practice for progressive DIPG. A phase I-II trial should be 
planned to test the best dose range.  
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Purpose/Objective: The number of elderly people with 
cervical cancer is increasing and elderly patients have age-
related problems related to morbidity. In this study, we 
evaluate pelvic radiation treatment tolerance of elderly 
cervical cancer patients treated with concurrent 
chemoradiotherapy.  
Materials and Methods: We retrospectively reviewed electric 
medical records of 102 cervical cancer patients treated with 
chemoradiotherapy from April 2007 to Feb 2014. Patients 
received concurrent radiation therapy with weekly cisplatin 
chemotherapy followed by intracavity radiotherapy. Patients 
were divided into nonelderly (ages < 70) (n = 65) and elderly 
(ages > 70) (n = 37) groups. The patient Charson comorbidity 
index, treatment factor and clinical parameters including 
pretreatment complete blood count were analyzed to 
identify treatment tolerance.  
Results: Elderly patients had a higher comorbidity index than 
younger patients. (p = 0.002) But, there was no significant 
difference in treatment compliance (treatment interruption ≥ 
2 days) to chemoradiotherapy between two groups. There 
was no significant difference in treatment related toxicity 
between the groups. In univariate and multivariate analyses, 
comorbidity index was significantly associated with 
treatment compliance (p = 0.011).  
Conclusions: Comorbidity index rather than age would be a 
predictive factor for pelvic treatment tolerance. Personalized 
supportive care considering patient status for cervical cancer 
is needed during treatment.  
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Purpose/Objective: Oncological treatment of older 
population has many unresolved questions, mainly due to low 
accrual of these patients into clinical trials. However, in 
everyday clinical practice an oncologist has to decide which 
treatment-guidelines are applicable for these patients. In this 
study, the treatment approach and rate of complications in 
elderly patients with locally advanced rectal cancer were 
evaluated.  
Materials and Methods: A retrospective review of medical 
records of patients who were treated with a curative intent 
for rectal carcinoma between January-2005 and December-
2011 was conducted. Two age groups were included: group-A: 
> 80-years (the study group), group-B: 65-75 years-old (a 
control group). Extracted data included demographics, co-
morbidities, treatment protocols, toxicity and time of death. 
Results: A total of 71 patients (35-group A, 36-group B) were 
included. Mean age was group A=83.5-years (range 80-96) and 
group B=70-years (range 65-75).The groups were well-
balanced with regards to co-morbidities, blood-tests, TRUS T-
stage, tumor location and timing of surgery with regards to 
radiotherapy. Radiotherapy without chemotherapy was given 
to 69% of group A compared to 22% of patients in group B 
(p<0.0001). During radiotherapy there were no significant 
difference with regards to early discontinuation, treatment 
interruptions, total dose and treatment toxicity. This 
treatment was given during planned hospitalization in 26% in 
group A compared to 5.4% in group B (p=0.022). 
Chemotherapy was given in 31% of patients in group A: 82% of 
initial 5-fluorouracil dose was less than 75%; additional dose-
reduction was needed in 63%, and in 45% of the patients the 
treatment was prematurely stopped, only 2 patients received 
capecitabine. In group B more patients received 
chemotherapy (78%), and in 93% of the patients the initial 
dose was more than 75%. There were no significant 
differences in a type of surgical procedure. The median 
survival in group A was 36.4 months and 31.2 months in group 
B (p=0.49). The mortality rate was 77% and 54% (p=0.05) 
respectively.  
Conclusions: Old age has significant implications on the 
treatment decision for initial chemotherapy-dose and need of 
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planned hospitalization. Full course of radiotherapy can be 
safely used in older patients but they have a low tolerance to 
chemotherapy and frequently require dose-reduction; the 
effect of this chemotherapy is uncertain.  
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Purpose/Objective: Various guidelines, including UK NICE 
guidance recommend a minimum of 74 Gy for prostate cancer 
radiotherapy. So we escalated prostate radiation dose to 74 
Gy (2Gy per #) in our department. We previously found that 
elderly patients were able to tolerate radiotherapy (RT) very 
well when median RT dose was 70 Gy (Data published 2006). 
Following RT dose escalation, we analysed our prospectively 
collected, rectal toxicity data in our department. 
Materials and Methods: All patients (pts) treated with 
prostate radiotherapy between August 2010 and July 2011, 
were identified from MOSAIC Software (Elekta). Pts who had 
prostate-bed radiotherapy, whole pelvis RT or HDR boost 
were excluded. The regional ethics committee advised that 
formal ethics approval was not necessary. 
Results: 132 patients were identified; median age was 70.5 
years, ( range 53 to 81 yrs). Median PSA was 13 (range 4.2 to 
133). Gleason scores: G6 4.5%, G7 51.5%, G8 21.2%, G9 18.2% 
G10 2.3% (missing data 2.3%). Tumour stage: T1 8.3%, T2 
55.3%, T3 32.6%, T4 0% (missing data 3.8%). Median total 
radiation dose was 74Gy (range 66Gy to 78Gy). (66 Gy is an 
outlier due to dosimetric problems caused by bilateral hip 
replacement). Age was significantly associated with rectal 
toxicity. Patients aged over 75 were almost 3.5 times more 
likely to develop ≥ grade 2 toxicity (p=0.026). Absolute total 
rectal volume outlined ( in cc) was also significantly 
associated with rectal toxicity. Pts having maximum rectal 
volume of more than 46cc were 3.8 times more likely to 
develop ≥ grade 2 toxicity (p=0.03 chi squared test). The 
rectal DVH parameters for 30Gy, 50Gy, and 60Gy were 
significantly associated with rectal toxicity .(p=0.038; 
p=0.016 and p=0.002 respectively). The absolute-volume 
parameters were consistently and better correlated with 
rectal toxicity than percentage-volume parameters. Median 
absolute rectal volume for patients with ≥grade 2 acute 
rectal toxicity was significantly higher than for those with 
grade 0/1 toxicity (p=0.018). By contrast, the difference 
between median percentage-Volume was not significant 
(p=0.345). The following Absolute-volume DVH constraints 
were most significantly correlated with rectal toxicity. 
V30≤42cc, V50≤40cc, V60≤35cc. 
Conclusions: Our real world data, from an unselected 
population of pts indicate elderly pts ( > 75 years) are at 
increased risk of rectal toxicity. If rectal DVH parameters are 
not optimal, elderly prostate pts should be considered for 
radiation dose reduction as patient preference studies 
indicate that lot of patients prefer lower toxicity over 
efficacy. (van Tol-Geerdink et al. J Clin Oncol. 2006: 24: 
4581). 
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Purpose/Objective: The incidence of cancer in the elderly is 
expected to rise . For example in the USA it is estimated that 
it will rise by 67% between 2010 to 2030. This is a 
retrospective analysis audit on radiotherapy to the very 
elderly defined as patients above 80 years old from Jan 2012 
until Dec 2013. We hope to analyse the radiotherapy intent; 
tumour site analysis and median survival days from the last 
fraction of radiotherapy. With these understanding, we hope 
to be able to further better or understanding and plan 
management for our very elderly who are under our care in 
future. 
Materials and Methods: We retrospectively collected and 
analysed the data from our Aria database for all patients 
above 80 years old on the day they finished treatment from 
January 2012 until Dec 2013. 
Results: We treated 1571 patients who were very elderly 
during these analysed 2 years. 40% of our very elderly were 
treated with radical intent. Nearly 25% of them were patients 
treated for Breast Cancer followed by Lung Cancer (20%). 
There was nearly an equal distribution with 51% of them 
being male patients. The median days from time of last 
fraction of radiotherapy to death was 129 days with a 
maximum of 826 days at time of analysis. Palliative 
treatments to the very elderly were mainly palliation for 
bone metastases and lung/ chest palliation. 
Conclusions: There is a high proportion of the very elderly 
treated with radical intent with radiotherapy; with Breast 
and Lung Cancer being the highest malignant cause. There 
was a fairly equal sex distribution between those treated for 
radiotherapy in the very elderly. We need to further analyse 
these data to provide a more meaning insight in order to 
improve and adequately support our very elderly requiring 
treatment. 
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Purpose/Objective: the incidence of esophageal cancer is 
increasing. Additionally, an increasing number of patients are 
older than 75 years. Since the publication of the CROSS trial 
in 2012, preoperative chemoradiation (CRT) followed by 
